Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trametinib-Resistant Melanoma Cells Displaying MITFhigh/NGFRlow/IL-8low Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge.

International journal of molecular sciences - 26 Apr 2023

Koziej Paulina, Kluszczynska Katarzyna, Hartman Mariusz L, Czyz Malgorzata

Abstract excerpt

Despite significant advances in targeted therapies against the hyperactivated BRAFV600/MEK pathway for patients with unresectable metastatic melanoma, acquired resistance remains an unsolved clinical problem. In this study, we focused on melanoma cells resistant to trametinib, an agent broadly used in combination therapies. Molecular and cellular changes were assessed during alternating periods of trametinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interleukin-8
Share to Melanoma

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Microphthalmia-Associated Transcription Factor

Share to Nerve Tissue Proteins

Share to Proto-Oncogene Proteins B-raf

Share to Pyridones

Share to Pyrimidinones

Share to Receptors, Nerve Growth Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 37175614
DOI: 10.3390/ijms24097891
PMCID: PMC10178474

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trametinib-Resistant Melanoma Cells Displaying MITFhigh/NGFRlow/IL-8low Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge.PMID 37175614Read ↗

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.Semantic proximity Read ↗

A neural crest stem cell-like state drives nongenetic resistance to targeted therapy in melanomaSemantic proximity Read ↗

Intermittent treatment of BRAFV600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge.Semantic proximity Read ↗

Tracking of Melanoma Cell Plasticity by Transcriptional ReportersSemantic proximity Read ↗

Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells.Semantic proximity Read ↗

Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation ProgramSemantic proximity Read ↗

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant MelanomaSemantic proximity Read ↗

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.Semantic proximity Read ↗

Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance reveals P2RX7 as an indicator of early drug response.Semantic proximity Read ↗

A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanomaSemantic proximity Read ↗

Rapidly induced drug adaptation mediates escape from BRAF inhibition in single melanoma cellsSemantic proximity Read ↗

NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.